Local Institution - 0312

Zunyi, Guizhou 563000

0 studies enrolling now · 1 studies all time

What they study most

Breast Cancer

Studies at this site

• Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer — Completed